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Background: While recent research has shown that expression of RABEX-5 in breast cancer and colorectal cancer
has a crucial impact on tumor development, there is little information regarding RABEX-5 expression in prostate
cancer. This study investigated the expression of RABEX-5 in prostate cancer by real time quantitative polymerase
chain reaction and evaluated its association with clinicopathological variables, including prostate cancer patient
prognosis.
Methods: A total of 180 patients with primary prostate cancer treated by radical prostatectomy were enrolled. Real
time quantitative polymerase chain reaction was utilized to investigate mRNA expression level of RABEX-5 in 180
paired prostate cancer/adjacent non-cancerous tissues. RABEX-5 mRNA expression was divided into high expression
group and low expression group and correlations between RABEX-5 mRNA and clinicopathological factors were
then evaluated. Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the
association between RABEX-5 mRNA expression and prognosis of patients with prostate cancer.
Results: Our study showed that RABEX-5 mRNA was significantly upregulated in prostate cancer tissues. The
data indicated that high expression of RABEX-5 mRNA was significantly associated with lymph node metastasis
(P = 0.001), clinical stage (P = 0.004), biochemical recurrence (P = 0.009), preoperative prostate-specific antigen
(P < 0.001), and Gleason score (P < 0.001). High RABEX-5 mRNA expression was a significant predictor of poor
biochemical recurrence free survival and overall survival both in univariate and multivariate analysis.
Conclusion: This is to our knowledge the first report investigating tumor RABEX-5 mRNA expression level in prostate
cancer. We have shown that high RABEX-5 mRNA expression is a strong predictor of poor prognosis in prostate cancer
patients treated by radical prostatectomy, and multivariate analysis confirmed RABEX-5 mRNA as an independent
prognostic factor.Background
Prostate cancer is the second most common cancer in
men and account for approximately 28,170 deaths in 2012
[1]. Even when prostate cancer is apparently confined to
the prostate, it encompasses a broad spectrum of prostate
cancer, some of which are characterized by extremely
indolent behavior and others by very poor outcome [2,3].
Recent efforts have focused on developing effective
biomarkers that provide clinicians with the improved
ability to identify clinically significant prostate cancer and* Correspondence: xymnwk@163.com
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question is how aggressively to treat prostate cancer
patients. Prostate cancer patients and clinicians are in
need of more accurate biomarkers to predict the
prognosis of prostate cancer, especially for intermediate
grade tumors. Few biomarkers have been reported
that reliably predict treatment failure. New prognostic
biomarkers are therefore required.
Rab-type small GTPases are conserved membrane
trafficking proteins in all eukaryotes, and they mediate
various steps in membrane trafficking, including vesicle
movement along cytoskeletons, vesicle docking to specific
membranes, vesicle budding, and vesicle fusion [4,5].
Rabs function as a molecular switch by cycling between
two nucleotide-bound states, a GDP-bound inactive stateLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Rabs are activated by specific guanine nucleotide exchange
factors, which promote the release of GDP from Rab
and binding of GTP to Rab, and the activated Rabs
are then inactivated by GTPase-activating proteins or
spontaneously inactivated by their intrinsic GTPase
activity [6], either of which terminates the cycle [6,7].
Therefore, the identification and characterization of
these Rab regulators, especially of GEFs, is crucial to
understanding the spatiotemporal regulation of Rab
GTPase activation.
The small GTPase RAB-5, which is found at the
plasma membrane and early endosomes, is a master
regulator of early endocytic trafficking [8]. Like other
small GTPases, RAB-5 is activated by an exchange of
bound GDP with GTP, which is catalyzed by a family of
guanine-nucleotideexchange factors. RABEX-5 was
identified as an interactor of Rabaptin-5 and was found to
possess GEF activity toward RAB-5 and related GTPases.
Likewise, both Rabaptin-5 and RABEX-5 are essential for
RAB-5-driven endosome fusion in vitro [9].
Aberrant RABEX-5 expression may result in obstruction
of the RAB-5-mediated endocytic vesicle fusion process,
thereby causing defects in phagocytosis. The results
showed that RABEX-5 was overexpressed in colorectal
cancer and breast cancer [10,11]. The data indicated that
RABEX-5 may act as an oncogene that is involved in the
formation and development of malignant tumors and
might influence tumor biological behavior. However, the
role and mechanism of action of RABEX-5 in prostate
cancer have not yet been studied. In present study, we first
analyzed the expression of RABEX-5 in prostate cancer
tissue by real time quantitative polymerase chain reaction.
Subsequently, the association between RABEX-5 and
prostate cancer clinicopathological factors was evaluated.
Additionally, we assessed the influence of RABEX-5 mRNA
expression on the biochemical recurrence free survival and
overall survival of patients with prostate cancer.
Tissue specimens
A total of 180 human prostate cancer and paired adjacent
noncancerous tissues were obtained from the second
hospital of Tianjin medical university, which underwent
radical prostatectomy at this hospital between 1999 and
2010 [12-14]. Written informed consent was obtained
from all prostate cancer patients and this study was
approved by the research ethics committee of Tianjin
medical university (TMUhMEC2013011). This investigation
conformed to the principles outlined in the Declaration of
Helsinki. Demographic and clinicopathological data of
prostate cancer patients were collected from medical
records. None of the prostate cancer patients received
androgen deprivation treatment, chemotherapy, or radiation
therapy prior to radical prostatectomy. The tissue sampleswere snapfrozen in liquid nitrogen and stored at −80°C
until used. The histopathology of each specimen was
reviewed on the HE-stained tissue section to confirm
diagnosis and tumor content at least 70% of prostate
cancer cells in the tissue samples. The following bio-
chemical and clinicopathological parameters were
recorded: biochemical relapse, preoperative serum
prostate-specific antigen, clinical stage, lymph node
status, angiolymphatic invasion status, Gleason score,
margin status, and seminal vesicle invasion status.
The time to biochemical recurrence was defined as
the period between radical prostatectomy and the
measurement of two successive values of serum
prostate-specific antigen level ≥ 0.2 ng/ml.Quantitative real-time polymerase chain reaction
Total RNA was isolated from the 180 pairs of prostate can-
cer tissue and adjacent noncancerous tissues using TRIZOL
reagent (Invitrogen). RNA was reverse-transcribed using
SuperScript First Strand cDNA System (Invitrogen)
according to the manufacturer’s instructions. The RABEX-5
sense primer was 5′-TTGGACAGATGGAATTGCAA-3′,
and the antisense primer was 5′-GTTGCAGTGGTGGAG
GAAGT-3′. For the β-actin gene, the sense primer
was 5′-ATAGCACAGCCTGGATAGCAACGTAC-3′,
and the antisense primer was 5′-CACCTTCTACAAT
GAGCTGCGTGTG-3′. Quantitative real-time polymerase
chain reaction was conducted using SYBR Green polymer-
ase chain reaction master mix (Applied Biosystems) in a
total volume of 20 μl on the 7900HT fast Real-time
polymerase chain reaction system (Applied Biosystems) as
follows: 50°C for 2 minutes, 95°C for 15 minutes, 40 cycles
of 95°C for 15 seconds, and 60°C for 60 seconds. A
dissociation procedure was performed to generate a
melting curve for confirmation of amplification speci-
ficity. β-actin was used as the reference gene. The
relative levels of gene expression were represented as
ΔCt = Ctgene- Ctreference, and the fold change of
gene expression was calculated by the 2-ΔΔCt Method.
Experiments were repeated in triplicate.Statistical analysis
Statistical analysis was performed using SPSS version
17.0. Quantitative real-time polymerase chain reaction
data were analyzed using Student’s t-test and expressed as
mean ± SD. The correlation between RABEX-5 mRNA
expression and the clinicopathological parameters was
assessed by Chi-square test. Kaplan-Meier and log-rank
tests were used when calculating the statistical significances
of the overall survival rate and biochemical recurrence free
survival rate, while COX regression analysis was used for
the univariate and multivariate analysis. Multivariate
survival analysis was performed on all parameters that were
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were considered statistically significant when P < 0.05.
Results
RABEX-5 mRNA expression is up-regulated in prostate
cancer tissues compared to adjacent noncancerous
tissues
Abnormally high RABEX-5 expression has been implicated
in colorectal cancer and breast cancer, but the pathological
function of RABEX-5 in prostate cancer has not been well
defined. Therefore, quantitative real-time polymerase chain
reaction analysis was performed on paired samples of
prostate cancer tissue and noncancerous tissue adjacent to
the cancer lesion isolated from the same patient. We
determined the levels of RABEX-5 transcript in samples
from prostate cancer and adjacent noncancerous tissues
using quantitative real-time polymerase chain reaction.
Our data reveal that RABEX-5 mRNA levels in the prostate
cancer tissues were significantly higher than those in the
adjacent non-cancerous tissues (Figure 1).
Relationship between RABEX-5 mRNA expression and
prostate cancer patients’ clinicopathological variables
The annotation of 180 prostate cancer patients
includes clinical outcomes, and in particular survival
and biochemical recurrence data, so we cross-checked
these data with RABEX-5 mRNA expression levels.
The 180 prostate cancer samples were subdivided into
two groups with respectively low or high amounts of
RABEX-5 mRNA. These groups were stratified by the
median value. In our prostate cancer cohort, the relation-
ship between the expression of RABEX-5 mRNA and
patient clinical and pathological characteristics was
shown in Table 1. High expression of RABEX-5 mRNAFigure 1 Identification of upregulated RABEX-5 mRNA
expression in prostate cancer tissues compared with its adjacent
non-cancerous tissues by real time quantitative polymerase chain
reaction. The data reveal that RABEX-5 mRNA levels in the prostate
cancer tissues were significantly higher than those in the adjacent
non-cancerous tissues (P < 0.05).was found to significantly correlate with lymph node
metastasis (P = 0.001), clinical stage (P = 0.004), preopera-
tive prostate-specific antigen (P < 0.001), biochemical
recurrence (P = 0.009), and Gleason score (P < 0.001). No
significant difference in RABEX-5 mRNA expression was
observed with age, surgical margin status, seminal vesicle
invasion, and angiolymphatic invasion (P > 0.05).
Relationship between clinicopathological variables,
RABEX-5 mRNA expression, and biochemical recurrence
free survival
In univariate survival analyses, cumulative survival curves
were calculated according to the Kaplan-Meier method.
Differences in survival times were assessed using the log
rank test. First, to confirm the representativeness of the
prostate cancer in present study, we analyzed established
prognostic predictors of prostate cancer patient survival.
Kaplan-Meier analysis demonstrated a significant impact of
well-known clinicopathological prognostic parameters, such
as seminal vesicle invasion, and Gleason score (P < 0.05,
Table 2). Assessment of biochemical recurrence-free
survival in total prostate cancer revealed that the high
expression level of RABEX-5 mRNA was correlated with
adverse biochemical recurrence free survival of prostate
cancer patients (Figure 2). Since variables observed to have
a prognostic influence by univariate analysis may covariate,
the expression of RABEX-5 mRNA and those clinicalo-
pathological parameters that were significant in univariate
analysis were further examined in multivariate analysis.
The results showed that the high expression of RABEX-5
mRNA was an independent prognostic factor for bio-
chemical recurrence-free survival (relative risk: 1.642, 95%
CI: 1.154-2.337, P = 0.006, Table 2). With regard to other
parameters, Gleason score or seminal vesicle invasion
status was shown to be an independent prognostic factor
for biochemical recurrence-free survival.
Relationship between clinicopathological variables,
RABEX-5 mRNA expression, and overall survival
In terms of overall survival, patients with high RABEX-5
mRNA expression had a poorer overall survival than
patients with low RABEX-5 mRNA expression. Prostate
cancer patients with high RABEX-5 mRNA expression had
shorter overall survival. Multivariate analysis indicated that
high amount of RABEX-5 mRNA was associated with
poorer overall survival, independently of classical clinical,
biological and pathological features such as Gleason score,
preoperative prostate-specific antigen, and prostate cancer
stage (Table 3). The detailed data between RABEX-5 mRNA
expression and overall survival are shown in Table 3.
Discussion
Prostate cancer is the most frequently diagnosed malignant
disease in men and the second leading cause of cancer
Table 1 Main characteristics of studies included in this meta-analysis
RABEX-5 mRNA expression
Variable Group High Low Total P value
Age 0.052
<70 55 (56.7%) 42 (43.3%) 97
≥70 35 (42.2%) 48 (57.8%) 83
Lymph node metastasis 0.001
Absence 75 (46.0%) 88(54.0%) 163
Presence 15 (88.2%) 2 (11.8%) 17
Surgical margin status 0.578
Absence 82 (49.4%) 84 (50.6%) 166
Presence 8 (57.1%) 6 (42.9%) 14
Seminal vesicle invasion 0.851
Absence 73 (50.3%) 72 (49.7%) 145
Presence 17 (48.6%) 18 (51.4%) 35
Clinical stage 0.004
T1 42 (40.8%) 61 (59.2%) 103
T2/T3 48 (62.3%) 29 (37.7%) 77
Preoperative PSA < 0.001
<4 1 (20%) 4 (80%) 5
4-10 20 (31.3%) 44 (68.7%) 64
>10 69 (62.2%) 42 (37.9%) 111
Gleason score
<7 29 (29.3%) 70 (70.7%) 99 <0.001
7 22 (64.7%) 18 (35.3%) 34
>7 39 (83.0%) 8 (17.0%) 47
Angiolymphatic invasion 0.346
Absence 75 (51.7%) 70 (48.3%) 145
Presence 15(42.9%) 20 (57.1%) 35
Biochemical recurrence 0.009
Absence 56 (43.8%) 72 (56.2%) 128
Presence 34 (65.4%) 18 (34.6%) 52
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major public health problem in the United States and
worldwide [1,12-14]. The treatment of prostate cancer with
radical prostatectomy, which may be combined with
chemotherapy, hormone therapy or radiation therapy, is
curative in many patients with prostate cancer. However,
most prostate cancer patients eventually relapse with
castration-resistant prostate cancer and develop meta-
static disease, which has a poor prognosis because no
effective treatments are currently available [15,16].
Although prostate-specific antigen screening has become
very common in the clinic, this marker lacks specificity
[17]. Up to 25% patients with prostate cancer have
prostate-specific antigen levels < 4.0 ng/ml, and elevated
prostate-specific antigen levels can also result frombenign prostatic disease [18]. A substantial proportion
of screen-detected prostate cancers may have been
overdiagnosed and subsequently overtreated, while
others may not have been detected and treated early
enough. The predictive value of conventional clinicopath-
ological parameters for powerful prognosticators, such as
pathological tumor stage and lymph node metastatic
disease, remains limited [19,20]. Widespread overtreatment
has greatly increased the social burden and poor quality of
life. Despite the generally good prognosis for early stage
prostate cancer patients, many affected individuals still die
as a result of metastasis and recurrence, which is the
major cause for most cancer-related deaths. Therefore, the
identification of reliable biomarkers for identifying
prostate cancer and predicting recurrence is critical
Table 2 Prognostic value of RABEX-5 mRNA expression for the biochemical recurrence free survival in univariate and
multivariate analyses by Cox regression
Univariate analysis Multivariate analysis
Covariant Exp (B) 95% CI P value Exp (B) 95% CI P value
RABEX-5 mRNA expression 1.716 1.207-2.439 0.003 1.642 1.154-2.337 0.006
Gleason score 1.703 1.280-2.265 <0.001 1.674 1.259-2.225 <0.001
Seminal vesicle invasion 1.505 1.132-2.003 0.005 1.443 1.084-1.920 0.012
Preoperative PSA 1.241 0.705-2.188 0.454
Angiolymphatic invasion 1.084 0.814-1.443 0.580
Surgical margin status 1.017 0.709-1.459 0.925
PCa Stage 1.090 0.921-1.291 0.316
Lymph node metastasis 1.140 0.850-1.528 0.381
Age 1.068 0.804-1.419 0.650
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therapeutic molecular targets of prostate cancers [21,22].
Therefore, it is urgent to seek and refine prognostic
variable, which is gained from pretreatment variables and
prostate cancer biopsy specimens in particular [19].
Abnormally high RABEX-5 expression has been
implicated in breast cancer and colorectal cancer, but the
function of RABEX-5 in prostate cancer has not been wellFigure 2 Associations between RABEX-5 mRNA expression and bioche
with prostate cancer. Patients with high RABEX-5 mRNA expression show
with low RABEX-5 mRNA expression (P < 0.001, log-rank test).studied. To date, an association between RABEX-5
expression and prostate cancer has not been reported.
Therefore, reverse transcription polymerase chain reaction
analysis was performed on paired samples of prostate
cancer tissue and noncancerous tissue adjacent to the
cancer lesion isolated from the same patient. Our data
showed that there is an elevation in RABEX-5 mRNA
expression in prostate cancer tissues compared to adjacentmical recurrence free time after radical prostatectomy in patients
ed significantly shorter biochemical recurrence free survival than those
Table 3 Prognostic value of RABEX-5 mRNA expression for the overall survival in univariate and multivariate analyses
by Cox regression
Univariate analysis Multivariate analysis
Covariant Exp (B) 95% CI P value Exp (B) 95% CI P value
RABEX-5 mRNA expression 1.629 1.038-2.555 0.034 1.751 1.098-2.792 0.019
Gleason score 2.526 1.788-3.568 <0.001 1.953 1.370-2.784 <0.001
Preoperative PSA 2.034 1.338-23.092 0.001 2.025 1.313-3.123 0.001
PCa Stage 4.131 2.888-5.911 <0.001 4.094 2.773-6.043 <0.001
Age 1.282 0.917-1.792 0.146
Angiolymphatic invasion 1.373 0.813-2.319 0.235
Surgical margin status 1.101 0.703-1.724 0.674
Lymph node metastasis 1.044 0.746-1.462 0.800
Seminal vesicle invasion 1.358 0.956-1.928 0.087
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between abnormal RABEX-5 mRNA expression and
clinicopathological factors. High expression of RABEX-5
mRNA was found to significantly correlate with
lymph node metastasis, clinical stage, preoperative
prostate-specific antigen, biochemical recurrence, and
Gleason score. In contrast, there were no significant
correlations between abnormal RABEX-5 mRNA expres-
sion and age, surgical margin status, seminal vesicle inva-
sion, and angiolymphatic invasion. This is the first study to
elucidate the clinicopathological significance of RABEX-5
mRNA expression in patients with prostate cancer.
In the present study we also have investigated the
prognostic impact of RABEX-5 mRNA in a previously
described cohort of 180 surgically resected prostate cancer
patients [12-14]. To confirm the representativeness of the
prostate cancer in present study, we analyzed established
prognostic predictors of prostate cancer patient survival.
The data showed a significant impact of well-known clin-
ical pathological prognostic parameters, such as seminal
vesicle invasion, and Gleason score. Assessment of
biochemical recurrence free survival in prostate cancer
revealed that the high expression level of RABEX-5 mRNA
was correlated with adverse biochemical recurrence free
survival of prostate cancer patients. Since variables ob-
served to have a prognostic influence by univariate analysis
may covariate, the expression of RABEX-5 mRNA and
those clinicalopathological parameters that were significant
in univariate analysis were further examined in multivariate
analysis. Multivariate analysis revealed that RABEX-5
mRNA expression was an independent predictor of bio-
chemical recurrence free survival. Our data demonstrate a
marked increase in RABEX-5 mRNA expression in tumors
compared to noncancerous tissue, with a significant and
independent relationship between high RABEX-5 mRNA
expressing tumors and reduced postoperative overall sur-
vival. It seems convincing that the high RABEX-5 mRNA
expression conferred a very unfavorable prognosis in ourstudy cohort. The high expression of RABEX-5 mRNA was
a significant indicator for predicting poor outcome after
radical prostatectomy. Therefore, a high RABEX-5 mRNA
expression may play an important role on the growth of
prostate cancer. This is the first study that demonstrates
RABEX-5 mRNA to be an independent prognosticator in
prostate cancer with high RABEX-5 mRNA expression
indicating poor outcome. The finding that patients with
high RABEX-5 mRNA expressing tumors have worse bio-
chemical recurrence free and overall survival than patients
with low RABEX-5 mRNA expressing tumors indicates that
RABEX-5 mRNA has the potential to be used as a useful
prognostic biomarker in prostate cancer. Consequently,
RABEX-5 mRNA expression, if validated in future studies,
could be used for selection of prostate cancer patients for
adjuvant treatment following radical prostatectomy. Over-
all, our data show that high RABEX-5 mRNA expression
profile correlates with poor prognosis in prostate cancer.
Conclusions
In conclusions, RABEX-5 was found to be overexpressed at
the mRNA level in prostate cancer samples examined
compared to adjacent non-cancerous tissues from the same
patient. Our current work demonstrates that RABEX-5
mRNA expression levels are associated with lymph node
metastasis, clinical stage, preoperative prostate-specific anti-
gen, biochemical recurrence, and Gleason score. RABEX-5
may play an important role in prostate cancer development.
Our study has laid a foundation for future investigations
to further explore the potential of RABEX-5 mRNA as a
diagnostic marker for monitoring biochemical recurrence
and as an effective therapeutic target for preventing and
treating prostate cancer.
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